GlomCon Foundation: Comprehensive Company Profile

Background

Overview

The GlomCon Foundation is a mission-driven nonprofit organization dedicated to advancing education, research, and patient support in the field of glomerular and other rare kidney diseases. Established in 2016 as an academic research collaborative at the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, GlomCon has evolved into a global consortium comprising nephrologists, clinicians, researchers, and patients united in their mission to transform kidney care.

Mission and Vision

GlomCon's mission is to provide medical education grounded in the best available evidence, free from commercial and ideological bias, and to create a platform for research collaboration among clinicians and academics, guided by the needs of patients and their caregivers. The organization envisions a world where nephrologists and care teams are equipped with the knowledge, tools, and community support necessary to improve outcomes for individuals living with glomerular and other rare kidney diseases.

Primary Area of Focus and Industry Significance

GlomCon focuses on the education, research, and support of nephrologists and healthcare professionals specializing in glomerular diseases. By fostering a global network and providing specialized training, the foundation plays a pivotal role in enhancing the understanding and treatment of these complex conditions, thereby significantly contributing to the nephrology community and improving patient care worldwide.

Key Strategic Focus

Core Objectives

• Education: Deliver high-quality, evidence-based medical education to nephrologists and healthcare professionals.

• Research Collaboration: Facilitate collaborative research efforts to advance the understanding and treatment of glomerular diseases.

• Patient Support: Provide culturally responsive support and resources for patients and caregivers affected by glomerular diseases.

Specific Areas of Specialization

GlomCon specializes in glomerular diseases, focusing on conditions such as IgA nephropathy, C3 glomerulopathy, and idiopathic membranoproliferative glomerulonephritis (IC-MPGN). The foundation addresses the unique challenges posed by these rare and complex kidney diseases through targeted education and research initiatives.

Key Technologies Utilized

GlomCon employs a range of technologies to support its initiatives, including:

• Virtual Platforms: For hosting seminars, workshops, and fellowship programs, enabling global participation.

• Data Management Systems: To manage real-world evidence studies and global registries.

• Open Access Publishing: Utilizing platforms for disseminating research findings.

Primary Markets or Conditions Targeted

The foundation primarily targets the global nephrology community, including clinicians, researchers, and healthcare professionals specializing in glomerular diseases. Additionally, GlomCon focuses on patients and caregivers affected by these conditions, aiming to improve their quality of life through education and support.

Financials and Funding

Funding History

As a nonprofit 501(c)(3) organization, GlomCon Foundation's funding primarily comes from grants, donations, and partnerships. In the fiscal year ending December 2023, the organization reported total revenues of $935,437 and expenses of $230,972.

Total Funds Raised

The foundation has successfully raised substantial funds to support its initiatives, with total revenues of $935,437 in 2023.

Notable Investors and Partners

GlomCon collaborates with various organizations and institutions to advance its mission, including:

• Baim Institute for Clinical Research: Entered into a research collaboration agreement to advance kidney disease research.

• American Kidney Fund and IgA Nephropathy Foundation: Partnered to develop a consensus framework for Centers of Excellence in Glomerular Disease Care.

• Novartis Pharmaceuticals Corporation: Collaborated on the CREATE Study, a real-world evidence patient registry for C3 glomerulopathy and IC-MPGN.

• Apellis Pharmaceuticals: Partnered for the CREATE Study to advance understanding and treatment of rare kidney diseases.

Intended Utilization of Capital

The funds raised are utilized to support GlomCon's educational programs, research initiatives, patient support services, and global outreach efforts. This includes hosting seminars, developing fellowship programs, conducting real-world evidence studies, and establishing Centers of Excellence in glomerular disease care.

Pipeline Development

Key Pipeline Candidates

GlomCon's pipeline focuses on:

• Educational Programs: Developing and expanding fellowship programs and certificate courses in nephrology.

• Research Initiatives: Conducting real-world evidence studies and global registries to advance understanding of glomerular diseases.

• Patient Support Services: Creating resources and support systems for patients and caregivers.

Stages of Clinical Trials or Product Development

While GlomCon does not conduct clinical trials directly, it collaborates with research institutions and pharmaceutical companies to support and facilitate such studies. For example, the partnership with Novartis and Apellis Pharmaceuticals on the CREATE Study involves real-world evidence collection and analysis.

Target Conditions

The foundation focuses on rare and complex kidney diseases, including:

• IgA Nephropathy

• C3 Glomerulopathy

• Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Relevant Timelines for Anticipated Milestones

GlomCon regularly hosts events and seminars to disseminate research findings and updates. For instance, the GlomCon Hawaii 2025 conference is scheduled for September 22-25, 2025, aiming to advance education, research, and collaboration in nephrology.

Technological Platform and Innovation

Proprietary Technologies

GlomCon utilizes proprietary platforms for:

• Educational Delivery: Hosting virtual seminars and fellowship programs.

• Data Management: Managing real-world evidence studies and global registries.

• Publishing: Disseminating research through open-access journals.

Significant Scientific Methods

The foundation employs various scientific methods, including:

• Real-World Evidence Studies: Collecting and analyzing data from clinical practice to inform research and treatment approaches.

• Consensus Frameworks: Developing guidelines and standards for Centers of Excellence in glomerular disease care.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, GlomCon's data management and research initiatives may incorporate advanced data analysis techniques to enhance understanding and treatment of glomerular diseases.

Leadership Team

Key Executive Profiles

• Ali Poyan Mehr, MD: Founding President of GlomCon Foundation, leading the organization's strategic direction and initiatives.

• Junelle Speller: Chief Strategy Officer, responsible for overseeing strategic planning and partnerships.

• Sarah Rayburn: Chief Operating Officer, managing day-to-day operations and program implementation.

• Rica Mae Pitogo: Administrative Director, overseeing administrative functions and support services.

Leadership Changes

Specific details regarding recent leadership changes are not available in the provided information.

Competitor Profile

Market Insights and Dynamics

The market for glomerular disease education and research is characterized by a growing need for specialized knowledge and collaborative efforts to address rare and complex kidney diseases. Organizations like GlomCon play a crucial role in filling this gap by providing education, fostering research collaborations, and supporting patient care.

Competitor Analysis

While specific competitors are not detailed, other organizations involved in nephrology education and research may include academic institutions, medical societies, and nonprofit organizations focused on kidney health. GlomCon differentiates itself through its global network, specialized focus on glomerular diseases, and comprehensive approach encompassing education, research, and patient support.

Strategic Collaborations and Partnerships

GlomCon has established several strategic collaborations to enhance its impact:

• Baim Institute for Clinical Research: Collaborated to advance kidney disease research through large, real-world evidence studies and global registries.